ADI Stock Recent News

ADI LATEST HEADLINES

ADI Stock News Image - prnewswire.com

WILMINGTON, Mass. , July 24, 2024 /PRNewswire/ -- July 24, 2024--  Analog Devices, Inc.  (Nasdaq:  ADI ) today announced it will release financial results for the third quarter fiscal year 2024 at 7:00 a.m.

prnewswire.com 2024 Jul 24
ADI Stock News Image - investorplace.com

The Nasdaq 100 is a list of the 100 most valuable companies traded on the Nasdaq index as measured by market capitalization. The Nasdaq index is generally associated with the technology sector.

investorplace.com 2024 Jul 23
ADI Stock News Image - investorplace.com

Nanotech stocks remain at the forefront of every tech-savvy investor's portfolio, considering the predicted worldwide nanotechnology market size in 2024 is $91.18 billion. Analysts project market size will reach $332.73 billion by 2032, with a CAGR of 17.6%.

investorplace.com 2024 Jul 23
ADI Stock News Image - zacks.com

In the most recent trading session, Analog Devices (ADI) closed at $237.72, indicating a -0.35% shift from the previous trading day.

zacks.com 2024 Jul 15
ADI Stock News Image - investorplace.com

These companies are some of the best picks for semiconductor stocks to buy now.  It's an interesting time for companies in the semiconductor business.

investorplace.com 2024 Jul 15
ADI Stock News Image - benzinga.com

In the fiercely competitive semiconductor industry, Nvidia Corp often captures the spotlight with its groundbreaking AI advancements. However, the industry's next major winners might not be the usual suspects.

benzinga.com 2024 Jul 15
ADI Stock News Image - zacks.com

In the most recent trading session, Analog Devices (ADI) closed at $233.74, indicating a -1.93% shift from the previous trading day.

zacks.com 2024 Jul 11
ADI Stock News Image - investorplace.com

There are more than 3,500 publicly listed companies in the U.S. today. Yet a handful of stocks get all the attention from the media, analysts and investors.

investorplace.com 2024 Jul 04
ADI Stock News Image - businesswire.com

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to evaluate ADI-270, an armored allogeneic “off-the-shelf” gamma delta chimeric antigen receptor (CAR) T cell therapy candidate targeting CD70.

businesswire.com 2024 Jun 24
ADI Stock News Image - zacks.com

Analog Devices (ADI) reported earnings 30 days ago. What's next for the stock?

zacks.com 2024 Jun 21
10 of 50